Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
140.50    3.25 (2.36%)
Bid:
138.00
Ask:
144.50
Spread: 6.50 (4.71%)
Market Cap: £110.25m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Xaar plc - Commercial partnership with Quantica

5 Jul 2023 09:00

RNS Number : 9635E
Xaar PLC
05 July 2023
 

5 July 2023

 

Xaar plc

 

Commercial partnership with Quantica

 

Xaar plc ("Xaar" or "the Group"), the leading inkjet printing technology group, and Quantica GmbH ("Quantica"), the multi-material 3D printing firm, have signed an exclusive commercial partnership to manufacture Quantica's NovoJet printheads, enabling ultra high viscosity printing for 2D and 3D printing applications. This partnership combines Xaar's expertise in inkjet printhead manufacturing with Quantica's ultra high viscosity printhead technology.

 

Manufacturing will take place at Xaar's high-tech facility in Huntingdon, with both companies expecting the initial NovoJet printheads to be shipping in Quantica's first 3D printers from the end of 2023. 

 

The agreement also gives Xaar commercial access to Quantica's IP in the jetting of highly viscous materials at up to 400cP at jetting temperature. This will complement Xaar's existing printheads and ImagineX technology portfolio which already enable jetting up to 100cP - far beyond other printheads available today.

 

Xaar will now offer the widest capability in printing high-performance materials to its OEM customers, meeting the opportunities for advanced manufacturing applications across electronics, display, industrial coating, adhesive and life-science sectors.

 

Founded in 2018 in Berlin, Quantica has dedicated its research and development efforts to both the novel NovoJet printhead technology and advanced multi-material 3D printers. By partnering with Xaar, a leader in inkjet printhead manufacturing, Quantica will further focus on the development of its 3D printing systems for applications in dental, medical, electronics, R&D, and more.

 

Graham Tweedale, Xaar's Chief Operation Officer, said:

 

"As we continue to accelerate our strategy the combination of our existing ImagineX technologies with the capability offered by Quantica's IP will ensure Xaar offers the widest range of solutions in jetting highly viscous materials."

 

Ramon Borrell, Chief Technology Officer for Quantica, said:

 

"Xaar is widely recognised for the quality of its printheads, and this agreement enables us to focus on delivering the roadmap of innovative NovoJet 3D printers for high performance multi-material parts with full confidence the printheads will deliver for our customers and partners."

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEZLFBXDLEBBF
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.